G. G. Jaliffe

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

P. Fasching, H. Rugo, K. Tamura, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE

P. Fasching, N. Harbeck, S. Johnston, 2021 .

236O_PRMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

M. Goetz, M. Campone, J. Huober, 2017 .

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

P. Neven, Chiun-Sheng Huang, H. Rugo, 2022, The Lancet. Oncology.